Loading…
LSTA
Lisata Therapeutics Inc
NASDAQ· Healthcare· Biotechnology· CUSIP 128058302
$1.69-7.14%Price as of Aug 29, 18:41 UTC · updated once a day, after the close
Key metrics
- Market cap
- $15.23M
- P/E
- —
- Forward P/E
- —
- P/B
- 1.9x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.51
- ROE
- -101.66%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.88
- 52-week high
- $5.07
- 52-week low
- $0.99
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -90.8% over 5Y.
today you would have $86.34▼ -91.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 16 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.86 | $2.98 | $2.73 | $2.53 | $12.60 | $21.45 | $37.65 | $53.40 | $52.65 | $42.45 | $162.00 | $565.50 | $1,023.00 | $900.00 | $765.00 | $2,115.00 | |
| P/E | — |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| HINDVyome Holdings, Inc | $2.21 | — | 2.6x | — | -999.17% | $15.48M |
| AEONAEON Biopharma, Inc. | $0.31 | — | — | — | — | $15.67M |
| NRSNNeuroSense Therapeutics Ltd. | $0.42 | — | — | — | -2174.98% | $15.88M |
| PASGPassage BIO, Inc. | $4.52 |
About the company
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. As of July 21, 2026, Lisata Therapeutics, Inc. operates as a subsidiary of Kuva Labs, Inc.
- 21
- Basking Ridge, United States
Company description provided by Yahoo Finance.